Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
PipCast®
PTE
Trade Marks
Webinars

Home / News / Pearce IP Blog

Pfizer announces hestitance to launch Amsparity in EU

by | Feb 28, 2020

Despite receiving CHMP approval earlier this month, Pfizer has announced it does not currently plan to launch Amsparity (adalimumab) in the EU, citing unfavourable market conditions.

Print Page
Mail Article

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Subscribe here

Our Latest News